A detailed history of Palo Alto Investors LP transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Palo Alto Investors LP holds 3,041,685 shares of IOVA stock, worth $24.8 Million. This represents 3.93% of its overall portfolio holdings.

Number of Shares
3,041,685
Previous 2,116,403 43.72%
Holding current value
$24.8 Million
Previous $17 Million 68.27%
% of portfolio
3.93%
Previous 2.15%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.28 - $11.9 $6.74 Million - $11 Million
925,282 Added 43.72%
3,041,685 $28.6 Million
Q2 2024

Aug 14, 2024

BUY
$7.78 - $14.19 $27,945 - $50,970
3,592 Added 0.17%
2,116,403 $17 Million
Q1 2024

May 15, 2024

BUY
$7.59 - $17.47 $45,684 - $105,151
6,019 Added 0.29%
2,112,811 $31.3 Million
Q4 2023

Feb 14, 2024

BUY
$3.3 - $8.89 $6.95 Million - $18.7 Million
2,106,792 New
2,106,792 $17.1 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.28B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Palo Alto Investors LP Portfolio

Follow Palo Alto Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.